Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Resistance, Drug Failure, and Disease Progression

Resistance, Drug Failure, and Disease Progression The clinical significance of the reduced in vitro susceptibility of HIV to antiretroviral agents has been difficult to elucidate for nucleoside analogs such as zidovudine. However, the virological significance of resistance to nevirapine and other HIV-1-specific reverse transcriptase inhibitors has been established. With antiretroviral therapy, disease progression is not equivalent to drug failure, which is not equivalent to drug resistance. Clinical disease progression is only indirectly linked to HIV replication. Drug resistance is complex, and combining drugs does not appear to delay emergence of resistant strains of HIV although it may affect the specific amino acid substitutions. Drug resistance does appear to contribute to drug failure. The clinical trial ACTG 116B/117 found that the duration of prior zidovudine therapy was not related to the relative benefit of switching to didanosine. Preliminary results of analysis of resistant strains of HIV isolated from ACTG 116B/117 patients revealed that the relative hazard of progression was about threefold higher for patients with high-level resistance to zidovu http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png AIDS Patient Care Mary Ann Liebert

Resistance, Drug Failure, and Disease Progression

AIDS Patient Care , Volume 8 (6) – Dec 1, 1994

Resistance, Drug Failure, and Disease Progression

AIDS Patient Care , Volume 8 (6) – Dec 1, 1994

Abstract

The clinical significance of the reduced in vitro susceptibility of HIV to antiretroviral agents has been difficult to elucidate for nucleoside analogs such as zidovudine. However, the virological significance of resistance to nevirapine and other HIV-1-specific reverse transcriptase inhibitors has been established. With antiretroviral therapy, disease progression is not equivalent to drug failure, which is not equivalent to drug resistance. Clinical disease progression is only indirectly linked to HIV replication. Drug resistance is complex, and combining drugs does not appear to delay emergence of resistant strains of HIV although it may affect the specific amino acid substitutions. Drug resistance does appear to contribute to drug failure. The clinical trial ACTG 116B/117 found that the duration of prior zidovudine therapy was not related to the relative benefit of switching to didanosine. Preliminary results of analysis of resistant strains of HIV isolated from ACTG 116B/117 patients revealed that the relative hazard of progression was about threefold higher for patients with high-level resistance to zidovu

Loading next page...
 
/lp/mary-ann-liebert/resistance-drug-failure-and-disease-progression-Z2WwgJzd2f
Publisher
Mary Ann Liebert
Copyright
Copyright 1994 Mary Ann Liebert, Inc.
ISSN
0893-5068
eISSN
1557-7449
DOI
10.1089/apc.1994.8.317
Publisher site
See Article on Publisher Site

Abstract

The clinical significance of the reduced in vitro susceptibility of HIV to antiretroviral agents has been difficult to elucidate for nucleoside analogs such as zidovudine. However, the virological significance of resistance to nevirapine and other HIV-1-specific reverse transcriptase inhibitors has been established. With antiretroviral therapy, disease progression is not equivalent to drug failure, which is not equivalent to drug resistance. Clinical disease progression is only indirectly linked to HIV replication. Drug resistance is complex, and combining drugs does not appear to delay emergence of resistant strains of HIV although it may affect the specific amino acid substitutions. Drug resistance does appear to contribute to drug failure. The clinical trial ACTG 116B/117 found that the duration of prior zidovudine therapy was not related to the relative benefit of switching to didanosine. Preliminary results of analysis of resistant strains of HIV isolated from ACTG 116B/117 patients revealed that the relative hazard of progression was about threefold higher for patients with high-level resistance to zidovu

Journal

AIDS Patient CareMary Ann Liebert

Published: Dec 1, 1994

There are no references for this article.